Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease.

Neumann U, Ufer M, Jacobson LH, Rouzade-Dominguez ML, Huledal G, Kolly C, Lüönd RM, Machauer R, Veenstra SJ, Hurth K, Rueeger H, Tintelnot-Blomley M, Staufenbiel M, Shimshek DR, Perrot L, Frieauff W, Dubost V, Schiller H, Vogg B, Beltz K, Avrameas A, Kretz S, Pezous N, Rondeau JM, Beckmann N, Hartmann A, Vormfelde S, David OJ, Galli B, Ramos R, Graf A, Lopez Lopez C.

EMBO Mol Med. 2018 Sep 17. pii: e9316. doi: 10.15252/emmm.201809316. [Epub ahead of print]

2.

Discovery of amino-1,4-oxazines as potent BACE-1 inhibitors.

Veenstra SJ, Rueeger H, Voegtle M, Lueoend R, Holzer P, Hurth K, Tintelnot-Blomley M, Frederiksen M, Rondeau JM, Jacobson L, Staufenbiel M, Neumann U, Machauer R.

Bioorg Med Chem Lett. 2018 Jul 1;28(12):2195-2200. doi: 10.1016/j.bmcl.2018.05.003. Epub 2018 May 3.

PMID:
29764741
3.

A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.

Neumann U, Rueeger H, Machauer R, Veenstra SJ, Lueoend RM, Tintelnot-Blomley M, Laue G, Beltz K, Vogg B, Schmid P, Frieauff W, Shimshek DR, Staufenbiel M, Jacobson LH.

Mol Neurodegener. 2015 Sep 3;10:44. doi: 10.1186/s13024-015-0033-8.

4.

Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid β-peptides.

Rueeger H, Lueoend R, Machauer R, Veenstra SJ, Jacobson LH, Staufenbiel M, Desrayaud S, Rondeau JM, Möbitz H, Neumann U.

Bioorg Med Chem Lett. 2013 Oct 1;23(19):5300-6. doi: 10.1016/j.bmcl.2013.07.071. Epub 2013 Aug 9.

PMID:
23981898
5.

World at work: bricklayers and bricklayers' assistants.

van der Molen HF, Veenstra SJ, Sluiter JK, Frings-Dresen MH.

Occup Environ Med. 2004 Jan;61(1):89-93. Review. No abstract available.

6.

N-phosphonoalkyl-5-aminomethylquinoxaline-2,3-diones: in vivo active AMPA and NMDA(glycine) antagonists.

Auberson YP, Acklin P, Bischoff S, Moretti R, Ofner S, Schmutz M, Veenstra SJ.

Bioorg Med Chem Lett. 1999 Jan 18;9(2):249-54.

PMID:
10021939
7.

5-Aminomethylquinoxaline-2,3-diones. Part II: N-aryl derivatives as novel NMDA/glycine and AMPA antagonists.

Auberson YP, Acklin P, Allgeier H, Biollaz M, Bischoff S, Ofner S, Veenstra SJ.

Bioorg Med Chem Lett. 1998 Jan 6;8(1):71-4.

PMID:
9871631
8.

5-Aminomethylquinoxaline-2,3-diones. Part I: A novel class of AMPA receptor antagonists.

Auberson YP, Bischoff S, Moretti R, Schmutz M, Veenstra SJ.

Bioorg Med Chem Lett. 1998 Jan 6;8(1):65-70.

PMID:
9871630
9.

Airborne concentrations, skin contamination, and urinary metabolite excretion of polycyclic aromatic hydrocarbons among paving workers exposed to coal tar derived road tars.

Jongeneelen FJ, Scheepers PT, Groenendijk A, Van Aerts LA, Anzion RB, Bos RP, Veenstra SJ.

Am Ind Hyg Assoc J. 1988 Dec;49(12):600-7.

PMID:
3213813
10.

1-Hydroxypyrene in urine as a biological indicator of exposure to polycyclic aromatic hydrocarbons in several work environments.

Jongeneelen FJ, Anzion RB, Scheepers PT, Bos RP, Henderson PT, Nijenhuis EH, Veenstra SJ, Brouns RM, Winkes A.

Ann Occup Hyg. 1988;32(1):35-43. No abstract available.

PMID:
3369793
11.

The Arnhem Lead Study. II. Indoor pollution, and indoor/outdoor relationships.

Diemel JA, Brunekreef B, Boleij JS, Biersteker K, Veenstra SJ.

Environ Res. 1981 Aug;25(2):449-56. No abstract available.

PMID:
7274205
12.

The Arnhem Lead Study. I. Lead uptake by 1- to 3-year-old children living in the vicinity of a secondary lead smelter in Arnhem, The Netherlands.

Brunekreef B, Veenstra SJ, Biersteker K, Boleij JS.

Environ Res. 1981 Aug;25(2):441-8. No abstract available.

PMID:
7274204

Supplemental Content

Loading ...
Support Center